a) Induction and maintenance of remission of ulcerative colitis; treatment of active Crohn's Disease. b) Treatment of rheumatoid arthritis which has failed to respond to non-steroidal anti-inflammatory drugs (NSAIDs).
Induction and maintenance of remission of ulcerative colitis; treatment of active Crohn's Disease.
CFS/ME affects up to 250,000 people in the UK and an estimated 17 million worldwide, however up to 90% of sufferers remain undiagnosed - Discover more
AIM ImmunoTech Inc. provided an update on its ongoing efforts to develop an effective therapeutic for “Long COVID” with its investigational drug, Ampligen.
The Bristol Myers Squibb-Pfizer Alliance presented results from ATHENS, a retrospective real-world data study, at the European Society of Cardiology(ESC) Congress 2023 showing that switching from Eliquis (apixaban) to rivaroxaban in Non-Valvular Atrial Fibrillation (NVAF) patients was associated with a higher risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than those who continued Eliquis.
In a late breaking trial session during EuroPCR 2023 in Paris, on behalf of the HOST-IDEA study investigators, Dr. Hyo-Soo Kim presented the results of a stent level analysis comparing two ultrathin strut drug-eluting stents (DES): Orsiro and Coroflex ISAR . The post-hoc comparison revealed significant differences in efficacy.
Vivus Inc. announced that it has entered into a License and Commercialization Agreement with Sanofi to commercialize avanafil on an...
Gilead Sciences, Inc.and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.
The FDA has allowed marketing of the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of multiple pathogens...